• Viatris Inc. recently reported positive top-line Phase 3 results in Japan for VR-205 (Nefecon), a targeted-release budesonide for adults with primary IgA nephropathy, showing clinically meaningful proteinuria reductions and kidney function improvements over a nine‑month treatment and three‑month follow-up period.
• The data, which align with global Phase 3 findings and support a planned New Drug Application in Japan by the end of 2026, highlight VR-205’s potential to address a high-incidence disease that drives a very large annual hemodialysis cost burden and limited disease‑modifying treatment options.
• We’ll now examine how the successful Japanese Phase 3 results for VR-205 in IgA nephropathy may influence Viatris’ broader investment narrative.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Viatris Investment Narrative Recap

To own Viatris today, you need to believe the company can slowly shift from a pressured generics base toward higher value, branded and complex therapies while keeping debt and pricing headwinds in check. The strong Phase 3 data for VR-205 in Japanese IgA nephropathy slightly strengthens the nearer term pipeline story, but the more immediate catalyst remains upcoming US and Japan regulatory decisions on late stage assets, while persistent pricing pressure in key markets still looks like the biggest risk.

Among recent announcements, the FDA’s acceptance of the NDA for fast acting meloxicam (MR-107A-02) for acute pain, with a December 27, 2026 PDUFA date, is particularly relevant. Together with VR-205’s Japan results, it underscores how Viatris is trying to build a branded, innovation driven earnings stream on top of its generics base, which could gradually change what really moves the stock if these filings translate into approvals and successful launches.

Yet even if VR-205 and other new products progress as hoped, investors should be aware that pricing pressure on the core generics portfolio could still...

Viatris' narrative projects $15.4 billion revenue and $954.5 million earnings by 2029. This requires 1.8% yearly revenue growth and a $1,251 million earnings increase from -$296.5 million today.

Uncover how Viatris' forecasts yield a $17.50 fair value, a 10% upside to its current price.

Exploring Other Perspectives

While VR-205’s success hints at upside beyond generics, the most bearish analysts were still only modeling about US$15.3 billion of revenue and US$469 million of earnings by 2029, showing how differently you and others might weigh this new data against long running concerns about pricing and leverage.

Explore 7 other fair value estimates on Viatris - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Viatris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viatris' overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 51 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.